Product Description
TAK-085 is an oral capsule medicine licensed to Takeda Pharmaceutical Company Ltd. TAK-085 contains omega-3 fatty acid ethyl (mainly, ethyl eicosapentaenoate (EPA-E) and ethyl docosahexaenoic acid (DHA-E)). (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01350999)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Hyperlipoproteinemias|Hyperlipidemia
Phase 3: Hypertriglyceridemia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
JapicCTI-163322 | N/A |
Completed |
Hyperlipidemia |
2017-08-30 |
|
Oasis Flow | P4 |
Completed |
Hyperlipoproteinemias|Hyperlipidemia |
2017-08-19 |
|
TAK-085/OCT-001 | P3 |
Completed |
Hypertriglyceridemia |
2011-01-01 |
|
TAK-085/CCT-002 | P3 |
Completed |
Hypertriglyceridemia |
2010-12-01 |